Company Profile

Mercia Pharma Inc
Profile last edited on: 11/14/13      CAGE: 4B4Z4      UEI: WKFRNG9Q8MT6

Business Identifier: Immunotherapies
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

111 Brewster Road
Scarsdale, NY 10583
   (607) 865-4557
Location: Single
Congr. District: 16
County: Westchester

Public Profile

Mercia Pharma Inc. is a privately held biotechnology company engaged in the discovery and development of disease-specific immunotherapeutic products. Mercia’s core adjuvanted self antigen immunotherapeutic technology was originally licensed from Aphton Corp. Using this approach, adjuvanted self-antigen immunotherapeutics targeting circulating hormones were clinically proven safe and effective in 1,500 patients, many of who were elderly and further immunocompromized by late stage cancer and chemotherapy. This technology has been further developed by Mercia to build a diverse pipeline of immunotherapeutic products. Based on this MERIT (MERcia Immunotherapeutic Technology) platform, products currently in development include therapeutics for Type 1 diabetes, Alzheimer’s disease, and asthma, and prophylactic products for seasonal and pandemic flu. Mercia is also researching future pipeline products for which disease-specific antigens have been identified. Each MERIT product is a unique construction designed to stimulate antigen-specific protective immune responses including antigen-specific regulatory T-cells, without provoking tissue destructive, cell-mediated inflammatory side effects. Immune tolerance to the patient’s own antigens are maintained and the risks of unwanted side effects, like autoimmunity or compromising the patient’s own ability to fight off infection, are avoided. Mercia’s corporate strategy is to focus on reducing risk and maximizing return by building a diverse pipeline of novel biological products, either by itself or with partners. Lead candidate discovery is conducted in collaboration with a number of academic experts. Subsequent development is streamlined because each pipeline candidate benefits from the extensive clinical safety and immunopharmacology database previously established with the core technology. A number of the company’s development programs have been initially supported by government funded grants. This has allowed Mercia to retain ownership and maximize its return on investment while developing a diverse pipeline of novel products. Mercia’s management team is experienced with a proven track record in pharmaceutical research, clinical and product development. Mercia’s team has taken a number of products based on the core technology into and through all stages of clinical development in both the US and Europe. Mercia has established GMP-compliant manufacture for its products through a strategic alliance with Nova Laboratories, UK. Proprietary aseptic processes have been implemented to provide materials to support clinical trials through commercial batch sizes using fully validated process technology. Mercia has a growing intellectual property portfolio on it’s un

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2009 2 NIH $599,108
Project Title: Therapeutic Vaccine For Asthma
2008 2 NIH $600,000
Project Title: Adjuvanted Influenza Vaccine

Key People / Management

  Peter Blackburn -- President

  Dimitrios T Drivas -- Chairman and Co-founder

  Dov Michaeli -- Medical Affairs

  Peter White -- Manufacturing